CTLA4-Ig: Began Phase II testing

Repligen Corp. (RGEN), Needham, Mass. Product: CTLA4-Ig Business: Transplant Therapeutic category: Immune suppression Target: B7 proteins on antigen-presenting cells Description: Soluble counter-rece...